期刊文献+

5-氨基酮戊酸介导的光动力对人增生性瘢痕成纤维细胞的影响 被引量:4

Effects of 5-aminolaevulinic acid-mediated photodynamic therapy on cultured dermal fibroblasts from hypertrophic scar
原文传递
导出
摘要 目的探讨5-氨基酮戊酸介导的光动力对人增生性瘢痕中成纤维细胞的影响。方法选取人增生性瘢痕增生期组织5例,体外培养其中的成纤维细胞。取培养后的第3、4代成纤维细胞,添加5-氨基酮戊酸培养后应用激光共聚焦显微镜检测其代谢产物原卟啉Ix在细胞内的积聚,并在5-氨基酮戊酸作用5h后给予635nm波长的红光照射,照射功率密度10mW/em。,能量密度0.5~8.0J/em。。24h后,应用CCK-8试剂盒分析5-氨基酮戊酸介导的光动力对成纤维细胞的杀伤作用。结果5-氨基酮戊酸作用4h后,成纤维细胞中有原卟啉IX的积聚;作用5h后,原卟啉Ix的积聚达到高峰,此时给予激光照射,成纤维细胞的成活率降低,并与照射强度呈量效依赖关系。结论5.氨基酮戊酸介导的光动力能够杀伤增生性瘢痕中的成纤维细胞,是一种治疗增生性瘢痕的新方法。 Objective To investigate the effects of 5-aminolaevulinic acid-mediated photodynamic therapy (5-ALA-PDT) on cultured dermal fibroblasts from hypertrophic scar. Methods Hypertrophic scar samples were obtained from 5 patients who underwent surgery. Dermal fibroblasts were isolated and then cultured in vitro. The 3rd or 4th generation fibroblasts were used and co-cultured with different concentrations of 5-ALA. Intracellular protoporphyrin IX (PpIX) was measured under laser confocal microscope. The cells treated with 5-ALA for 5 hours were irradiated by red laser (635 nm wavelength) at a power density of 10 mW/cm= with ener- gy density from 0.5 to 8.0 J/cm2. The cell survival was measured by CCK-8 Kit at 24 hours. Results Intra-cellular PpIX accumulation was observed at 4 hours after 5-ALA-treatment. The peak level of PpIX accumula- tion was achieved at 5 hours after 1 mmol/L 5-ALA treatment. Viable cells were decreased after laser irradiation at a dose dependent manner with energy density. Conclusion Dermal fibroblasts from hypertrophic scar could efficiently accumulate PpIX by exogenous 5-ALA administration and be killed by laser irradiation. It is a new method to prevent clinical hyperplastic scar from formation.
出处 《中国美容整形外科杂志》 CAS 2011年第7期405-408,共4页 Chinese Journal of Aesthetic and Plastic Surgery
基金 国家自然科学基金资助项目(81071565)
关键词 5-氨基酮戊酸 光动力疗法 增生性瘢痕 成纤维细胞 5-aminolaevulinic acid Photodynamic therapy Hypertrophic scar Fibroblasts
  • 相关文献

参考文献12

  • 1PALM M D, GOLDMAN M P. Safety and efficacy comparison of blue versus red light sources for photodynamic therapy using methyl aminolevulinate in photodamaged skin [ J ]. J Drugs Dermatol, 2011,10(1) :53-60.
  • 2ORTNER M A. Photodynamic therapy for cholangiocarcinoma: o- verview and new developments [ J ]. Curt Opin Gastroenterol, 2009,25 (5) :472-476.
  • 3USUDA J, ICHINOSE S, ISHIZUMI T, et al. Outcome of photo- dynamic therapy using NPe6 for bronchogenie carcinomas in cen- tral airways > 1.0 cm in diameter [ J]. Clin Cancer Res, 2010,16 (7) :2198-2204.
  • 4DAV1DSON S R, WEERSINK R A, HAIDER M A, et al. Treat- ment planning and dose analysis for interstitial photodynamic thera- py of prostate cancer [ J ]. Phys Med Biol, 2009,54 ( 8 ) : 2293- 2313.
  • 5SACZKO J, CHWILKOWSKA A, KULBACKA J, et al. Photooxi- dative action in cancer and normal cells induced by the use of pho- tofrin in photodynamie therapy[ J]. Folia Biol (Praha), 2008,54 ( 1 ) :24-29.
  • 6ISHIZUKA M, ABE F, SANO Y, et al. Novel development of 5- aminolevurinie acid (ALA) in cancer diagnoses and therapy [ J ]. Int Immunopharmaeol, 2011,11 ( 3 ) : 358-365.
  • 7COUPIENNE I, BONTEMS S, DEWAELE M, et al. NF-kappaB inhibition improves the sensitivity of human glioblastoma ceils to 5- aminolevulinic acid-based photodynamic therapy [ J ]. Biochem Pharmacol, 2011,81 ( 5 ) :606-616.
  • 8CHEN X, ZHAO P, CHEN F, et al. Effect and mechanism of 5- aminolevulinic acid-mediated photodynamic therapy in esophageal cancer[J]. Lasers Med Sci, 2011,26( 1 ) :69-78.
  • 9SINGH G, ALQAWI O, ESPIRITU M. Metronomic PDT and cell death pathways[ J]. Methods Mol Biol, 2010,635:65-78.
  • 10REDBORD K P, HANKE C W. Topical photodynamic therapy for dermatologic disorders : results and complications [ J ]. J Drugs Dermatol, 2007,6(12) : 1197-1202.

同被引文献67

  • 1Gauglitz GG,Korting HC,Pavicic T,et al.Hypertrophic scarring and keloids:pathomechanisms and current and emerging treatment strategies[J].Mol Med,2011,17(1-2):113-125.
  • 2Cai H,Gu Y,Sun Q,et al.Effect of hematoporphyrin monomethyl ether-mediated photodynamic therapy on hypertrophic scar fibroblasts[J].Photodermatol Photoimmunol Photomed,2011,27(2):90-96.
  • 3Moan J,Peng Q.An outline of the hundred-year history of PDT[J].Anticancer Res,2003,23(5A):3591-3600.
  • 4Lang K,Schulte KW,Ruzicka T,et al.Aminolevulinic acid(Levulan)in photodynamic therapy of actinic keratoses[J].Skin Therapy Lett,2001,6(10):1-2.
  • 5Mendoza J,Sebastian A,Allan E,et al.Differential cytotoxic response in keloid fibroblasts exposed to photodynamic therapy is dependent on photosensitiser precursor,fluence and location of fibroblasts within the lesion[J].Arch Dermatol Res,2012,304(7):549-562.
  • 6Saczko J,Chwilkowska A,Kulbacka J,et al.Photooxidative action in cancer and normal cells induced by the use of photofrin in photodynamic therapy[J].Folia Biol(Praha),2008,54(1):24-29.
  • 7Jarvi MT,Niedre MJ,Patterson MS,et al.Singlet oxygen luminescence dosimetry(SOLD)for photodynamic therapy:current status,challenges and future prospects[J].Photochem Photobiol,2006,82(5):1198-1210.
  • 8Brancaleon L,Moseley H.Lasers and non-laser light sources for photodynamic therapy[J].Lasers Med Sci,2002,17(3):173-186.
  • 9Britton JE,Goulden V,Stables G,et al.Investigation of theuse of the pulsed dye laser in the treatment of Bowen's disease using 5-aminolaevulinic acid phototherapy[J].Br J Dermatol,2005,153(4):780-784.
  • 10Ibbotson SH,Jong C,Lesar A,et al.Characteristics of 5-aminolaevulinic acid-induced protoporphyrin Ⅸfluorescence in human skin in vivo[J].Photodermatol Photoimmunol Photomed,2006,22(2):105-110.

引证文献4

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部